SCHEMBL10077384

SCHEMBL10077384

CC(C)(CNC(=O)CC(Cc1cc(F)ccc1F)NC(=O)OBr)CNC(=O)[C@@H](O)[C@H](N)COCc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.34
CTSS P25774 2/20 0.34
CTSB P07858 2/20 0.33
MC4R P32245 1/20 0.33
DPP4 P27487 2/20 0.33
DPP7 Q9UHL4 2/20 0.33
DPP9 Q86TI2 1/20 0.33
SCN9A Q15858 1/20 0.32
LAP3 P28838 2/20 0.32
ANPEP P15144 1/20 0.32
RNPEP Q9H4A4 1/20 0.32
DNPEP Q9ULA0 1/20 0.32
MMP12 P39900 1/20 0.32
PSMB11 A5LHX3 1/20 0.32
PSMD11 O00231 1/20 0.32
PSMD12 O00232 1/20 0.32
PSMD14 O00487 1/20 0.32
PSMA7 O14818 1/20 0.32
PSMD3 O43242 1/20 0.32
PSMC3 P17980 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078259 0.93 SYK (0.37) RENCTSSCTSBMC4RPSMB1
SCHEMBL10074722 0.93 SYK (0.37) RENCTSSCTSBMC4RPSMB1
SCHEMBL10074471 0.93 SYK (0.37) RENCTSSCTSBMC4RPSMB1
SCHEMBL10078267 0.89 REN (0.37) RENCTSSCTSBMC4RDPP4
SCHEMBL10074129 0.89 REN (0.37) RENCTSSCTSBMC4RDPP4
SCHEMBL10074716 0.89 REN (0.37) RENCTSSCTSBMC4RDPP4
SCHEMBL10078062 0.89 CTSS (0.40) RENCTSSSCN9ACTSDPPARA
SCHEMBL10074326 0.88 DPP4 (0.41) RENDPP4DPP7DPP9
SCHEMBL10074457 0.88 DPP4 (0.41) RENDPP4DPP7DPP9
SCHEMBL10078263 0.86 CTSS (0.35) RENCTSSCTSBMC4RSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 REN 449/4885CTSS 43/4885CTSB 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.